Video

William G. Wierda on the Treatment of CLL

Author(s):

William G. Wierda

CURE spoke with Wierda at the 2015 Chemotherapy Foundation Symposium, a meeting of over 1,000 oncologists and oncology professionals.

William G. Wierda, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the treatment of chronic lymphocytic leukemia (CLL). CURE spoke with Wierda at the 2015 Chemotherapy Foundation Symposium, a meeting of over 1,000 oncologists and oncology professionals in early November.

Related Videos
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Bald Doctor.
Dr. Anna Arthur is the Director of the Medical Nutrition Science Program, as well as a tenure-track Assistant Professor in the Department of Dietetics and Nutrition at the University of Kansas Medical Center.
Dr. Ritu Salani, the Director of Gynecologic Oncology at the University of California, Los Angeles (UCLA), UCLA Health, and a board-certified gynecologic oncologist.
Image of Dr. Scott Kopetz
Image of Dr. Susumu Hijoka
Image of Dr. Braun.
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Dr. Michael Bogenschutz
Related Content
Image of man with black hair.
February 3rd 2025

Rybrevant Alone and in Combo With Chemo is Efficacious in HER+ mCRC

Ryan Scott
Dr. Filippo Pietrantonio discusses OrigAMI-1 trial data which assessed Rybrevant in mutated, wild-type, non-HER2-amplified metastatic colorectal cancer.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Illustration of blood cells.
January 28th 2025

Brukinsa May Improve Efficacy Versus Imbruvica in R/R CLL and SLL

Spencer Feldman
Brukinsa had a lower risk of disease progression or death versus Imbruvica, as well as a more favorable safety profile, in R/R CLL and SLL.
A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More
January 22nd 2024

A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More

Alex Biese Brielle Benyon
We take a look at the first FDA approval in the oncology space for 2024, the Lymphedema Treatment Act and more.
An image of a doctor taking notes.
January 24th 2025

Whitesnake Guitarist John Sykes Died of Cancer, Mike Peters Starting CAR-T

Alex Biese
From the deaths of John Sykes and former Planned Parenthood President Cecile Richards to an update from Mike Peters, here’s this week’s cancer news.
Illustration of blood cells.
January 21st 2025

Glucarpidase May Improve Renal Outcomes in Lymphoma, Leukemia

Ryan Scott
Patients with lymphoma or leukemia with methotrexate-induced acute kidney injury experienced improved renal outcomes following glucarpidase treatment.